Differential persistence of transmitted HIV-1 drug resistance mutation classes

Journal of Infectious Diseases

Volumn 203, Issue 8, 2011, Pages 1174-1181

  Jain, Vivek ^a   Sucupira, Maria C ^c   Bacchetti, Peter ^a   Hartogensis, Wendy ^a   Diaz, Ricardo S ^c   Kallas, Esper G ^c,d   Janini, Luiz M ^c   Liegler, Teri ^a   Pilcher, Christopher D ^a   Grant, Robert M ^b   Cortes, Rodrigo ^c   Deeks, Steven G ^a   Hecht, Frederick M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNINDEXED SEQUENCE; UNITED STATES; VIRUS LOAD; VIRUS MUTATION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; RNA, VIRAL; YOUNG ADULT;

EID: 79953293934     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq167     Document Type: Article

References (48)

1. Chaix M-L, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23:717-24.
2. Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673-8.
3. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200:1503-8.
4. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-80.
5. Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21:2223-9.
6. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41:236-42.
7. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81:3037-41.
8. Gonzalez LM, Brindeiro RM, Aguiar RS, et al. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 2004; 48:3552-5.
9. Paredes R, Sagar M, Marconi VC, et al. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 2009; 83:2038-43.
10. Zimmer JM, Roman F, Lambert C, et al. Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. J Acquir Immune Defic Syndr 2008; 48:255-62.
11. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-9.
12. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82:5510-8.
13. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-61.
14. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37:1570-3.
15. Smith DM, Wong JK, Shao H, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007; 196:356-60.
16. Brenner B, Routy J-P, Quan Y, et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 2004; 18:1653-60.
17. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-52.
18. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-17.
19. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16:1119-29.
20. Kallas EG, Bassichetto KC, Oliveira SM, et al. Establishment of the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS) strategy in the city of Sao Paulo, Brazil. Braz J Infect Dis 2004; 8:399-406.
21. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-23.
22. Grant RM, Kuritzkes DR, Johnson VA, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003; 41:1586-93.
23. Kuritzkes DR, Grant RM, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the opengene DNA sequencing system. J Clin Microbiol 2003; 41:1594-9.
24. Sucupira MC, Caseiro MM, Alves K, et al. High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS 2007; 21:116-28.
25. de Ronde A, van Dooren M, van Der Hoek L, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75:595-602.
26. Bellamy SL, Li Y, Ryan LM, Lipsitz S, Canner MJ, Wright R. Analysis of clustered and interval censored data from a community-based study in asthma. Stat Med 2004; 23:3607-21.
27. Sparling YH, Younes N, Lachin JM, Bautista OM. Parametric survival models for interval-censored data with time-dependent covariates. Biostatistics 2006; 7:599-614.
28. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.
29. Chan KC, Galli RA, Montaner JS, Harrigan PR. Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection. AIDS 2003; 17:1256-8.
30. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20:795-803.
31. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71:1089-96.
32. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-52.
33. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192:1537-44.
34. van Maarseveen NM, Wensing AM, de Jong D, et al. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. J Infect Dis 2007; 195:399-409.
35. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-9.
36. Brenner BG, Roger M, Moisi DD, et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008; 22:2509-15.
37. Toni TA, Asahchop EL, Moisi D, et al. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 2009; 53:1670-2.
38. Oette M, Kaiser R, Däumer M, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. AIDS 2006; 41:573-81.
39. Chaix ML, Desquilbet L, Descamps D, et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: AaNRS Resistance Network. Antivir Ther 2007; 12:1305-10.
40. Brown AJ. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci U S A 1997; 94:1862-5.
41. Rouzine IM, Coffin JM. Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci U S A 1999; 96:10758-63.
42. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus type 1- infected individuals: the relative roles of drift and selection. J Virol 2000; 74:6262-8.
43. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-72.
44. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of ,50 copies/ml receiving combination therapy. JAMA 2001; 286:196-207.
45. Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452-65.
46. Persaud D, Siberry GK, Ahonkhai A, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004; 78:968-79.
47. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010; 84:6241-7.
48. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008: 105:7552-7.